DOCK1 and triple-negative breast carcinoma: For example, RRP15 can inhibit the growth of liver cancer cells by inducing senescence and apoptosis (29); RRP1B can upregulate the expression of claudin-1 by depleting DOCK1, and increase cell viability and motility of low-density breast cancer cells (30); RRP8 can be used as a novel biomarker for triple-negative breast cancer (31).